Brief: Hookipa Says First Patient Dosed In Phase 1/2 Clinical Trial For HB-201

So-Young International

30/12/2019 12:42

Dec 30 (Reuters) - Hookipa Pharma Inc  HOOK.O :
    * HOOKIPA ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2
CLINICAL
TRIAL FOR HB-201 FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS
16-POSITIVE CANCERS
    * HOOKIPA PHARMA - EXPECTS TO PROVIDE INTERIM SAFETY, DOSE
ESCALATION, AND EFFICACY DATA FROM HB-201 IN LATE 2020 OR EARLY
2021

Source text for Eikon:  ID:nGNXbMx5Jj 
Further company coverage:  HOOK.O 

 ((Reuters.Briefs@thomsonreuters.com;))